RA was well tolerated in the Phase I trial. Now MBX is planning a Phase II trial in post-bariatric hypoglycaemia patients.

There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

Studies in patients with type 2 diabetes are needed to further assess and allow comparison of several GLP-1RA agents' impact on steady-state pharmacokinetics and pharmacodynamics of concomitant ...

Financing was co-led by Forbion and General Atlantic, with participants such as RA Capital Management, OrbiMed, and Lilly ...

Glucagon-like peptide 1 receptor agonists (GLP-1RA) are transforming the treatment of obesity and type 2 diabetes. As an approach to optimize efficacy and minimize side effects, co-agonists ...

Just when you thought there couldn’t be investor appetite for yet another GLP-1-focused obesity biotech, Verdiva Bio has ...

Topline data were announced from a phase 3 trial evaluating CagriSema in overweight or obese patients without type 2 diabetes.

If a person decides to start GLP-1RA treatment, careful monitoring is essential to quickly identify any worsening of eating disorder behaviors, such as the development of extreme dietary ...

The most notable decrease in obesity was in the South, the study says, noting that that’s the area with “the highest observed per capita GLP-1RA dispensing rate.” Steve Christo/Corbis/Corbis ...

“The most notable decrease was in the South, which had the highest observed per capita GLP-1RA dispensing rate.” One author ...

The South also had the highest rate per capita of GLP-1RA dispensing at 6% compared with 5.1% for those living in the Midwest, 4.4% for those in the Northeast and 3.4% for those in western states.